Sponsor content
336 result(s) found, displaying 141 to 150
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Australian public assessment report (AusPar)Enhertu (trastuzumab deruxtecan) for treatment of unresectable or metastatic HER2 positive breast cancer.
-
Designation or determinationPriority review
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Budesonide / glycopyrronium / formoterol
-
Prescription medicine decision summaryTGA Decision: Saphnelo (anifrolumab) is approved to treat adult patients with active systemic lupus erythematosus (SLE).
-
Australian public assessment report (AusPar)Forxiga (dapagliflozin) has been approved for reducing the risk of progressive decline in kidney function in adults with
proteinuric chronic kidney disease. -
-
Designation or determinationProvisional determination
-